Fujitsu, a global technology company, has partnered with Paradigm Health, a US-based clinical trial platform provider, to improve clinical trials and address drug loss in Japan.
The partnership aims to streamline medical institution data collection and processing, accelerate clinical trial planning, and attract global trials to Japan. Fujitsu will leverage its Healthy Living Platform, Kozuchi AI service, and a new Patient-centric Clinical Trials service using a proprietary LLM to automate document creation.
This collaboration seeks to modernize clinical trials in Japan, increase patient accrual, decrease drug development timelines and costs, and establish Japan as a key player in the global clinical trials ecosystem. Fujitsu aims to secure JPY 20 billion (USD 138 million) in revenue by fiscal 2030 through these efforts.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.